Bharatbook.com has added this latest report “The Future of the Biologicals Market” to their extensive collection of market research reports. This report analyzes the three main components of the biopharma market – monoclonal antibodies, therapeutic proteins and vaccines – to show why these groups have such a positive future. It provides an up-to-date discussion of the whole biopharma market and explores new clinical indications beyond those already targeted. rbhc0258
Features and benefits
* Gain an insight into the strengths and limitations of the biopharma market and identify those product groups whose strengths are to drive growth
* Analyze of recent R&D developments with a perspective on the important research avenues now being pursued.
Evaluate the 3 major segments of the biopharma market and the contribution of biopharma in the management of major diseases.
* Analyze the possible avenues for new product development and the new technologies that can be utilized.
Identify areas of low growth because of a lack of good new products and identify key national/regional markets and developing markets opportunities.
Highlights
In terms of market size, therapeutic proteins are the leaders, but monoclonal antibodies (mAbs) are the fastest growing sector. By the end of 2009 there were 29 mAbs approved and marketed for therapeutic use. This product class is now approaching maturity.
Cancer still ranks high among targets for new mAbs development, along with treatments for inflammation/immune related diseases including rheumatoid arthritis and multiple sclerosis. Cytokines in advanced development include treatments for cancers, benign prostatic hyperplasia, gout and inflammatory conditions such as Crohn’s disease.
The global vaccine market is fairly evenly divided between pediatric and adult vaccines, each accounts for about half of the total vaccine market in value terms In volume terms, there is far greater disparity, because most pediatric vaccines are low-cost, commodity items.
Your key questions answered
* What indications will be the main market drivers for mAbs during the next five years?
* Will the biopharma market perform any better than the overall pharma market during the next five years, and why?
* Which segments of the therapeutic protein market are likely to see the best growth?
* What are the major drivers for M&A activity in the biopharma market and will the US continue to be the dominant market in the global biopharma market?
* Which ‘big pharma’ companies have the biggest stake in the biopharma sector and which biopharma companies have shown the strongest performance?
For more information kindly visit: http://www.bharatbook.com/detail.asp?id=133976&rt=The-Future-of-the-Biologicals-Market.html
Related Reports:
Preclinical Development of Monoclonal Antibodies and Related Biologicals: Emerging technologies and new therapeutic candidates
http://www.bharatbook.com/detail.asp?id=133973&rt=Preclinical-Development-of-Monoclonal-Antibodies-and-Related-Biologicals-Emerging-technologies-and-new-therapeutic-candidates.html
British Biologicals-Company Report
http://www.bharatbook.com/detail.asp?id=137351&rt=British-Biologicals-Company-Report.html
Or
Contact us at :
Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: [email protected]
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatresearch.wordpress.com
